Study | Patients | Location | Time to Treatment (mean) | Complete Recovery | Incomplete Recovery | No Improvement |
---|---|---|---|---|---|---|
Birchall et al (1999)7 | 3 | PcomA | 2.3 days | 3 (100%) | 0 | 0 |
Mavilio et al (2000)14 | 6 | PcomA | 2 days to 6 mo (range) | 6 (100%) | 0 | 0 |
Kazekawa et al (2003)13 | 12 | PcomA-2/Cav-6/Car.ophth-2 | 13.7 mo | 5 (42%) | 4 (33%) | 3 (25%) |
Kim et al (2003)9 | 7 | PcomA-2/Cav-3/Basilar-2 | 11 mo | 2 (29%) | 3 (42%) | 2 (29%)a |
Stiebel-Kalish et al (2003)17 | 11 | PcomA | 9 days | 0 | 11 (100%) | 0 |
Chen et al (2006)18 | 6 | PcomA | 5.5 days | 4 (33%) | 2 (67%) | 0 |
Ahn et al (2006)21 | 10 | PcomA | Unknown | 6 (60%) | 3 (30%) | 1 (10%) |
Mansour et al (2007)15 | 11 | PcomA-6/Cav-5 | 10 weeks | 7 (64%) | 4 (36%)b | |
Hanse et al (2008)16 | 21 | PcomA | 1 to >14 days (range) | 8 (38.1%) | 11 (52.4%) | 2 (9.5%) |
Kassis et al (2010)20 | 20 | PcomA | 71 days | 7 (35%) | 12 (60%) | 1 (5%) |
Santillan et al (2010)19 | 11 | PcomA | ≤7 days | 7 (64%) | 2 (18%) | 2 (18%) |
Current study | 30 | PcomA-10/Cav-11/Post.circ-5/paraophth-4 | 48 days | 15 (50%) | 12 (40%) | 3 (10%) |
a No improvement or worsening.
b Incomplete recovery or no improvement.